Skip to main content
. Author manuscript; available in PMC: 2019 Dec 15.
Published in final edited form as: Cancer Res. 2018 Oct 17;78(24):6728–6735. doi: 10.1158/0008-5472.CAN-17-3370

Figure 2. Changes in AICDA and NFkB pathway expression.

Figure 2.

A) AICDA expression is significantly increased after treatment with four different TKIs in PC9 cell line: I) first generation TKI, gefitinb; II) first generation TKI, erlotinib; III) second generation TKI, afatinib; IV) third generation TKI, osimertinib. B) Expression of NFĸB pathway components after TKI treatment. No change in RelA expression (canonical pathway). The expression of RelB & P52 (non-canonical pathway) increased by multiple folds. C) NFkB ChIP assay. RELB and RNA polymerase II are recruited to the AICDA promoter region after 6hrs exposure to 8nM gefitinib. AICDA qPCR results are reported as a percentage of the total chromatin input. (* p>0.05; ** p<0.05)